FDA Seeks Input on Digital Health Technologies in Clinical Investigations for Drugs and Biological Products

Key Takeaways

• FDA requests stakeholder comments by June 1 2026.
• Focus on regulatory challenges, guidance, and workshop topics.
• Builds on PDUFA VII DHT progress and 2023 guidance.
• Aims to clarify data integrity and patient safety standards.
• Could accelerate DHT adoption in drug trials.

Pulse Analysis

The FDA’s latest Federal Register notice marks a decisive step toward embedding digital health technologies—such as wearables, mobile apps, and sensor‑based platforms—into the clinical investigation landscape for drugs and biologics. Since the launch of PDUFA VII, the agency has issued guidance on remote data capture and convened two of five planned workshops, signaling a clear policy trajectory. By soliciting stakeholder input, the FDA aims to translate rapid sensor advances into a coherent regulatory framework that can keep pace with industry innovation. The agency also emphasizes interoperability and real‑time analytics, urging manufacturers to adopt open standards that facilitate data sharing across trial sites and regulatory submissions.

For sponsors, the request presents a rare opportunity to influence the next wave of FDA guidance on digital endpoints, data validation, and cybersecurity requirements. Clarifying these regulatory expectations can reduce trial delays, lower costs associated with retrofitting legacy data collection methods, and improve patient recruitment by enabling remote monitoring. Moreover, a transparent framework will bolster confidence in digitally derived endpoints, facilitating their acceptance by payers and health technology assessment bodies worldwide. In addition, the FDA is expected to address the validation of algorithmic outputs, ensuring that machine‑learning models used in endpoint derivation meet rigorous performance thresholds.

Stakeholders must submit comments by June 1 2026, outlining real‑world challenges and proposing actionable solutions. The FDA has indicated that insights gathered will inform future guidance documents and shape upcoming public workshops, potentially covering disease‑specific digital endpoints and interoperability standards. Early engagement can give companies a competitive edge, ensuring their DHT strategies align with emerging regulatory expectations and positioning them to leverage richer, patient‑centric data streams in upcoming drug development programs. Companies that proactively align their DHT roadmaps with the forthcoming guidance can also streamline post‑approval monitoring, leveraging continuous data streams to satisfy post‑marketing surveillance obligations.